ePROLogo

One of the greatest challenges facing biomedical sciences in the 21st century is accelerating the development and approval of effective treatments for neurodegenerative diseases.

 

 

Important Links

Alzheimer Research Forum

Coalition Against Major Diseases (CAMD)

OUR UNIQUE MISSION

The mission of CAMD is to accelerate the development of therapies for neurodegenerative diseases by advancing drug development tools for regulatory approval.The members of CAMD work collaboratively to create new ways to identify patients with neurodegenerative diseases before symptoms are apparent, and develop tools to prevent or slow these diseases so patients can maintain independence and quality of life.

 

OUR GOALS

  • Create common data sharing standards to facilitate faster review by the U.S. Food and Drug Administration (FDA) and other global regulatory agencies;
  • Establish databases of standardized pharmaceutical clinical trial data as a tool to design more efficient clinical trials of new treatments, thereby allowing developers to more rapidly identify therapies that have a positive effect on disease progression;
  • Develop disease progression models to aid in the design of clinical trials; and
  • Identify biomarkers for use in selecting patients who are still early in their disease progression for clinical trials.

CAMD will not duplicate efforts already underway in these areas, but will instead leverage existing data and knowledge, and facilitate consensus on methods that will advance medical product development and make these new methods available for use by researchers around the world. These goals align with the objectives of a 2004 white paper known as the Critical Path Initiative, where the FDA called attention to an alarming decline in the number of innovative medical products being submitted for FDA approval, and cited the need for applied research to bridge the gap between basic scientific research and medical product development.

OUR COLLABORATORS

CAMD is comprised of members from the pharmaceutical industry, global regulatory agencies, patient advocacy groups, research foundations, academia, scientific associations, and consultant groups with an interest in neurodegenerative diseases.